the brand names reflect different FDA indications and dosing schedules
The weight loss one can achieve with Tirzepatide varies significantly based on individual circumstances, including the amount of weight to lose and any additional weight-related health concerns
Wegovy contains the same active ingredient as Ozempic (semaglutide) but is specifically FDA approved for weight management
Hydrate, eat, and go to bed safely
The FDA justified its decision to resolve the shortage by saying that the maker of tirzepatide drugs, Eli Lilly, had assured the agency that its product availability and manufacturing capacity can meet the present and projected national demand. However, the FDA cautioned that there still could be intermittent localized supply disruptions. In their lawsuit last week, compounders countered that the shortage remained and that the agency had simply taken Lillys word, which is self-interested in monopolizing the market. In a court filing Friday, the FDA appeared to back down, requesting that the lawsuit be placed on hold, essentially, so that the agency had the opportunity to reevaluate the decision at issue in this case. With its request, the FDA cited previous court rulings that set precedent for the agency to get a chance to reverse course
Control of gluconeogenesis by metformin: Does redox trump energy charge